Top Health Tech Companies With Best Stability & Growth (10,000+)

Investor Backing & Capital Strength: Capital raises and valuation step‑ups are prominent, including a $100M Series D in July 2024 at a reported $2.3B valuation to fund expansion into Medicare Advantage and Medicaid. Independent coverage and company materials corroborate the round and use of proceeds.

Market Expansion: Nationwide availability (all 50 states + D.C.) and moves into Medicare Advantage (targeted 51 markets by end‑2024) with Medicaid launches planned for 2025 broaden the addressable market. Company updates indicate these government lines are now active in select states.

Strategic Partnerships: Payer connectivity has accelerated from roughly 40 to 70+ plans with preferred‑network status at major carriers, and revenue scales with completed sessions rather than sign‑ups. These relationships underpin growing patient access and utilization.

Profitability: Profitability is described as sustained since 2023 while the company continues to scale, pointing to durable unit economics. Company updates also indicate cash‑flow positivity and that efficiency targets such as the Rule of 40 have been surpassed.

Strong Revenue Growth: Revenue growth is characterized as strong over multiple years with momentum continuing into 2026. Acceleration is described alongside expansion in provider supply and booking channels.

Strategic Partnerships: New distribution and integrations, including embedded real‑time booking on Yelp and a payer partnership, broaden patient access points and reinforce growth. These partnerships extend reach beyond the core site into high‑traffic consumer and member channels.

Strong Revenue Growth: Revenue is rising, with 2025 total revenue reaching roughly $147M and U.S. Galleri revenue about $136–137M. Early 2026 momentum continued as Galleri revenue increased to $39.8M on sharply higher test volumes (over 56,000 in Q1).

Strategic Partnerships: Distribution and access are expanding through integrations with Quest Diagnostics and Epic’s EHR that streamline ordering and broaden provider access. Additional channels such as Priority Health’s employer offering indicate widening availability.

Investor Backing & Capital Strength: Capital resources are sizable, including $823.1M in cash and securities as of March 31, 2026 and a $110M equity investment from Samsung entities. Management indicates a multiyear runway into 2030, supporting continued trials and commercialization.

Investor Backing & Capital Strength: Fresh capital arrived via a $50M April 2026 investment from Boehringer Ingelheim alongside an earlier Series C led by Dassault Systèmes/Medidata, extending resources for commercialization. The concurrent transfer of CT‑155 commercialization/marketing rights signals committed funding tied to revenue‑bearing activities.

Strategic Partnerships: Long‑running collaborations deepened with Boehringer Ingelheim (commercialization rights for CT‑155) and Otsuka (Rejoyn), while Dassault Systèmes/Medidata broadened a technology partnership to support scale‑up. A January 2026 partnership with Ultrahuman expands reach beyond traditional PDT channels.

Product Line Growth: Recent FDA authorizations for CT‑132 (episodic migraine) and Rejoyn (MDD) broaden the platform and advance the company toward launches. These milestones are highlighted as bolstering credibility for future products.

Strong Revenue Growth: Top line continues to expand year over year, with both U.S. and international operations contributing and management guiding to continued growth. Momentum from specialty volumes and global logistics supports ongoing expansion.

Profitability: Earnings power is rising, reflected in higher adjusted operating income and an upgraded full‑year EPS outlook. Specialty‑focused acquisitions are cited as accretive to gross profit and operating margin.

Strong Market Position & Advantage: Scale in a concentrated U.S. distribution market and leadership in specialty services underpin a durable competitive position. Long‑dated commercial ties and a broad global footprint add resilience to growth.

Strong Revenue Growth: Revenue growth is portrayed as robust, with recent commentary indicating continued year-over-year momentum at nine-figure scale.

Market Expansion: Expansion beyond the office into education, hospitality, and other commercial settings, along with entry into the UK and Ireland, points to active geographic and vertical growth.

Product Line Growth: A shift to a broader connected beverage platform with new offerings and refreshed hardware signals widening product scope.

Strong Revenue Growth: Revenue momentum is described as surpassing $200M in annual recurring revenue with sustained hypergrowth over five years as of mid-2026. These disclosures are presented alongside press coverage as the clearest signal of rapid expansion.

Investor Backing & Capital Strength: Capital scale is underscored by a $250M Series E led by Andreessen Horowitz in 2025 and sizeable total funding, paired with a multibillion-dollar valuation cited in coverage. This late-stage financing is tied to expansion plans in healthcare and housing as well as hiring and office growth.

Strong Market Position & Advantage: Adoption signals point to broad penetration in U.S. multifamily, including widespread use among large operators and a meaningful share of apartments nationwide. High-visibility distribution and portfolio rollouts reinforce a defensible position in its core market.

Investor Backing & Capital Strength: Significant late-stage financing, including an $88M Series C (April 2024) and a $150M Series D (March 2026) at a reported ~$3B valuation, is presented as fuel for continued scale. These rounds are explicitly tied to expanding product capabilities, the provider network, and payer/employer channels.

Strategic Partnerships: Expanded collaborations are highlighted, including a June 2026 research partnership with Stanford and broad access via 125+ insurer relationships, with added employer and health‑system programs (e.g., EAP‑to‑insurance continuity, Amazon, Circle Medical). These linkages signal deeper distribution and credibility across stakeholders.

Market Expansion: Operational reach appears to be widening through national payer coverage (including Medicare/Medicaid), employer routes, and health‑system integrations alongside a provider network cited around 26,000. Utilization markers such as 7M visits in 2025 and active hiring/office expansion indicate scaling across markets.

Strong Revenue Growth: Public disclosures indicate revenue surpassed $1B in 2023 and remained above that level in 2024–2025, with 2024 noted at roughly $1.1B. These signals point to ongoing top‑line expansion.

Product Line Growth: Recent launches and releases such as IntelliCare and the 2026.1 updates for IRIS, IRIS for Health, and Health Connect highlight an active roadmap. This cadence is presented as expanding the addressable market and creating new upsell paths.

Strong Market Position & Advantage: Industry recognition places the company as a Leader in the 2026 Gartner Magic Quadrant for Enterprise EHRs and the 2025–2026 IDC MarketScape for analytical databases, alongside multiple 2026 Best in KLAS #1 rankings. These placements signal competitive strength and buyer traction in core markets.

Investor Backing & Capital Strength: Recent financing includes a June 2024 seed and an October 2025 $15.5M Series A led by Costanoa with Town Hall Ventures and Khosla, positioned to fund hiring, product, and market expansion. Public investor and media materials describe this capital as intended to scale operations and partnerships.

Market Expansion: Operations are described as growing beyond New York into New Jersey and Ohio, with compliance entities in multiple states and localized, multilingual school pages signaling multi‑district deployment. District approvals and company updates point to a widening on‑the‑ground footprint.

Strategic Partnerships: Public district materials (e.g., Millville Public Schools and Upper Deerfield Township in NJ) announce Marble programs, indicating active school partnerships. Company communications highlight a school‑centered model built specifically for schools, reinforcing this partnership‑led growth.

Strong Revenue Growth: Recent results show double‑digit top‑line increases (FY2025 and Q1 2026), and management’s FY2026 outlook implies continued double‑digit expansion. Quarterly growth of 24% in Q4 2025 and 22% in Q1 2026 underscores momentum.

Profitability: Margins are described as strong with adjusted EBITDA around 42–43% and a swing to positive GAAP net income. This profitability profile continued into Q1 2026 alongside growth.

Customer Loyalty & Retention: Net revenue retention near 111–112% indicates expanding spend from existing clients. Growth in customers contributing over $100K annually (up ~15–16%) reinforces durable relationships.

Investor Backing & Capital Strength: Capital raised is described as substantial, with a $372M Series D in June 2024 led by a16z and participation from Sanofi, explicitly earmarked to grow the pipeline and AI platform. References to $600M+ in total funding and ongoing hiring point to a reinforced capital base supporting expansion.

Strategic Partnerships: Collaborations with Sanofi and OpenAI are presented as first-in-class efforts to apply AI across drug development, signaling external validation and increased resourcing. A 2025 Sanofi licensing deal worth up to €545M further indicates the capability to progress and transact assets with blue‑chip partners.

Product Line Growth: Pipeline activity is shown to be broadening via in‑licensing (e.g., a CNS‑penetrant TYK2 inhibitor in Dec 2025) and movement into the clinic, including first‑in‑human dosing on June 9, 2026. Together, these moves suggest more programs are entering and advancing through clinical stages.

Strong Market Position & Advantage: PatientPoint is described as the nation’s largest digital point‑of‑care network, citing roughly 30,000–35,000 physician offices and about 145,000 screens, signaling outsized scale. Expanded Media Rating Council accreditation in April 2026 across its full screen network can further strengthen advertiser confidence and budgets.

Product Line Growth: In 2026 the company launched programmatic buying via PatientPoint Health Audiences and introduced a Consumer Health Network for CPG/OTC brands, broadening monetization avenues. These moves are positioned to expand the addressable revenue beyond traditional pharma channels.

Investor Backing & Capital Strength: Advent International signed a definitive agreement to acquire PatientPoint in August 2025, framed as a catalyst to accelerate network expansion and product innovation. Such backing is presented as a strong vote of confidence in both the company and the point‑of‑care media category.

Strong Hiring & Retention: Active recruiting is evident with 20+ open roles on Indeed across multiple states and functions, alongside a LinkedIn size band of 51–200 and recent activity signaling team buildout. Role postings span therapists, a remote RN health advocate, and operations/partnerships positions, indicating capacity expansion.

Market Expansion: Medicare-covered virtual therapy is marketed across all 50 states with state-by-state pages and booking via channels like Zocdoc, pointing to an enlarging go-to-market footprint. Site and blog updates through 2025–2026 and a market-launch role (e.g., Philadelphia) further support ongoing geographic growth.

Strategic Partnerships: A publicly announced collaboration with Advanced Nursing & Home Care and recent LinkedIn partnership/event posts suggest growing referral networks. These signals align with efforts to embed within senior-care ecosystems to broaden distribution.

Investor Backing & Capital Strength: A $120M Series C reported on June 18, 2024 provides substantial runway to scale a late‑stage health‑AI model. Industry trackers such as CB Insights and Becker’s cite this funding event, indicating fresh capital support.

Product Line Growth: Multiple launches in 2024–2025—Authorization Advisor, AKASA Medical Coding, and CDI Optimizer—signal an expanding roadmap and deeper coverage of mid‑cycle workflows. This cadence reflects ongoing investment to widen solution breadth.

Strategic Partnerships: A collaboration with Cleveland Clinic announced in April 2025 and deepened in October 2025 highlights enterprise‑scale deployment of AKASA’s GenAI tools. Coverage of real‑world outcomes (e.g., Nebraska Methodist’s reported gains) points to deployments beyond pilots.

Investor Backing & Capital Strength: Recent funding activity—including a reported portion of a $30M+ round in July 2026 alongside a $28.1M Series B in 2023—signals strengthened runway to support operations and selective scaling. This momentum points to renewed capacity to invest in growth after a difficult 2025.

Market Expansion: A multi-state footprint with launches and active operations across Florida, Michigan, Ohio, Virginia, and Washington reflects continued geographic reach. Active job postings and partner-facing materials further indicate ongoing expansion activity aimed at Medicaid/Medicare populations with SMI.

Strategic Partnerships: Payer-facing positioning and reported collaborations with large platforms (e.g., Carelon Behavioral Health) show ongoing engagement with Medicaid managed care organizations. These arrangements suggest continued commercial traction in value-based models for SMI populations.

Investor Backing & Capital Strength: Significant 2025 funding—$35M Series A in March and $100M Series B in September—was explicitly framed to scale teams, deployments, and AI capabilities, with the Series B described as the largest technology raise in senior living at the time. These funds are presented as providing runway to expand nationwide and accelerate product development.

Product Line Growth: The offering broadened in 2025 with the launch of a unified senior‑living ecosystem, adding an emergency call system and later Inspiren HQ with the Inspiren Intelligence analytics engine. This positions the platform as an integrated suite spanning resident safety, care planning, staffing, and emergency response.

Market Expansion: Operator deployments and partnerships (e.g., Arrow Senior Living’s 27 communities, Solera portfolio outcomes, and integrations like August Health) signal expanding footprint and workflow fit in senior living. Dated milestones across 2025–2026 reference a more than doubled customer base and a “year of record growth,” consistent with scaling activity.

Innovation-Driven Growth: Product updates and launches, including AI features and benchmarking reports, appear on a frequent cadence, signaling ongoing investment in new capabilities and data-driven tools. This pattern suggests a forward-leaning roadmap aligned to emerging needs in assisted living.

Strategic Partnerships: An expanding ecosystem of integrations and recently added partners across payments, remote monitoring, and other categories points to a platform strategy that deepens utility and stickiness. This breadth of connections indicates growing interoperability within senior-living tech stacks.

Product Line Growth: The offering has broadened from a clinical EHR into an operating platform spanning CRM, billing, analytics, and AI, indicating increased coverage of operator workflows. Such expansion reflects efforts to capture more of the value chain within assisted-living operations.

Investor Backing & Capital Strength: Multiple late‑stage rounds since 2024, including a $72M Series C in 2025 and a reported $162M total raised, indicate robust external support and runway.

Strategic Partnerships: Named deals in 2026 with Zurich (UK), Transamerica, and Equitable, alongside claims of working with 8 of the top 10 U.S. life insurers, broaden access to millions of beneficiaries. Zurich UK provides independent confirmation of rollout.

Market Expansion: Geographic availability has widened from the U.S. into Canada and the U.K., supported by insurer and bank launches in 2025–2026. This expansion increases potential reach across North America and Europe.

Investor Backing & Capital Strength: An $80M Series C in April 2026 lifted total capital above $160M and put valuation near $1B, indicating strong capacity to fund AI and platform expansion. Participation from established investors (e.g., StepStone, Benchmark, Redpoint, ICONIQ, Atreides) reinforces financing stability.

Market Expansion: Customer adoption progressed to 500+ MedTech companies, including 16 of the top 20, up from milestones like 300 customers in 2025. Enterprise penetration across leading manufacturers underscores widening reach in its target vertical.

Product Line Growth: New offerings such as Care Journeys (launched 2024, expanded 2025), a Salesforce AppExchange product, a Snowflake Data Mart, and AcuityAI signal ongoing investment to broaden use cases. Expansion beyond commercial workflows toward the full product lifecycle further extends the platform’s scope.